Paul A Friedman sold $13M of MDGL
director at MADRIGAL PHARMACEUTICALS, INC.. 24,520 shares at an average of $522.39, traded Jan 9, 2026, filed Jan 13, 2026.
Score components
- +15RoleDirector
- +25Trade size$12.8M at market
- +5Share of holdings soldSold 12% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -4.1%, 3m +6.3%, 6m +8.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-001976, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 9, 2026 | MOption exercise Common Stock10b5-1 | +24,520 | $15.80 | $387k | 211,684 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -1,480 | $511.98 | $758k | 210,204 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -1,094 | $513.11 | $561k | 209,110 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -1,345 | $514.68 | $692k | 207,765 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -1,996 | $515.81 | $1.0M | 205,769 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -766 | $516.84 | $396k | 205,003 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -2,450 | $517.86 | $1.3M | 202,553 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -1,363 | $518.68 | $707k | 201,190 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -846 | $519.88 | $440k | 200,344 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -681 | $521.03 | $355k | 199,663 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -840 | $521.98 | $438k | 198,823 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -970 | $523.00 | $507k | 197,853 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -1,199 | $524.10 | $628k | 196,654 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -2,432 | $525.05 | $1.3M | 194,222 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -1,066 | $526.00 | $561k | 193,156 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -1,560 | $526.97 | $822k | 191,596 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -575 | $528.18 | $304k | 191,021 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -691 | $529.17 | $366k | 190,330 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -166 | $529.76 | $88k | 190,164 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -280 | $530.69 | $149k | 189,884 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -80 | $532.50 | $43k | 189,804 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -332 | $534.16 | $177k | 189,472 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -148 | $535.29 | $79k | 189,324 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -473 | $536.02 | $254k | 188,851 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -487 | $536.88 | $261k | 188,364 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -80 | $537.85 | $43k | 188,284 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -480 | $539.23 | $259k | 187,804 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -600 | $540.36 | $324k | 187,204 | Jan 13, 2026 |
| Jan 9, 2026 | SOpen-market sale Common Stock10b5-1 | -40 | $545.79 | $22k | 187,164 | Jan 13, 2026 |
| Jan 9, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -24,520 | $0.00 | $0 | 280 | Jan 13, 2026 |
Related signals
Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $6.2M 11,583 shares | -6% | |
| 30Weak | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $342k 664 shares | -5% | |
| 35Weak | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $1.4M 2,500 shares | -1% | |
| 21Weak | MADRIGAL PHARMACEUTICALS, INC. | David Soergel Chief Medical Officer | $517k 1,042 shares | -9% | |
| 33Weak | MADRIGAL PHARMACEUTICALS, INC. | Richard S Levy director | $2.9M 5,682 shares | -21% | |
| 40Moderate | MADRIGAL PHARMACEUTICALS, INC. | David Soergel Chief Medical Officer | $435k 844 shares | -7% | |
| 45Moderate | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier EVP and CFO | $854k 1,982 shares | -14% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $181k 419 shares | -3% | |
| 41Moderate | MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $155k 360 shares | -3% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Rebecca Taub Pres., R&D, and CMO | $212k 491 shares | -0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.